NervGen Pharma Corp.

Equities

NGEN

CA64082X2032

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 15:59:59 2024-05-14 EDT			5-day change	1st Jan Change
2.11 ^CAD	+0.48%		+4.46%	-21.85%

04-17	NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update	MT
04-17	NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

NervGen Pharma Corp. Expands Alzheimer's Disease, Scientific Advisory Board

July 12, 2021 at 08:34 am

NervGen Pharma Corp. announced the addition of three world-class scientists and clinical researchers to its Alzheimer's Disease Scientific Advisory Board. Drs. Martin Farlow, Reisa Sperling and Michael Weiner have agreed to join Drs. Jeffrey Cummings, Bruce Lamb, George Perry and Henrik Zetterberg on the Alzheimer's Disease Scientific Advisory Board to guide NervGen as it prepares for the Phase 1b clinical trial of its lead compound, NVG-291, in Alzheimer's patients that is slated to begin in 2022.

Latest news about NervGen Pharma Corp.

NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update	04-17	MT
NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	04-17	CI
NervGen Pharma Closes C$23 Million Bought Deal Financing	03-28	MT
NervGen Pharma Raising C$20.1 Million in Bought-Deal Offering of Share Units	03-21	MT
NervGen Pharma Corp. Plans to Initiate A New Study in Which Subjects Completes Open-Label Nvg-291	02-15	CI
NervGen Pharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
NervGen Pharma Corp. Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury	23-10-23	CI
Nervgen Pharma Appoints John Ruffolo to Board of Directors	23-10-17	CI
NervGen Pharma Corp. Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury	23-09-25	CI
NervGen Pharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Nervgen Pharma Corp. Receives Institutional Review Board Approval for Its Phase 1B/2A Proof-Of-Concept Clinical Trial Protocol of Its Proprietary Lead Compound, Nvg-291, in Individuals with Spinal Cord Injury	23-08-08	CI
NervGen Pharma Corp. Receives $3.18 Million Grant from Wings for Life to Support Upcoming Clinical Study in Spinal Cord Injury	23-06-27	CI
NervGen Pharma Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Nervgen Pharma Corp. Appoints Michael Kelly as CEO	23-04-10	CI
NervGen Pharma Appoints Michael Kelly as President & Chief Executive Officer	23-04-10	MT
NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
NervGen Pharma Reports Dosing of All Subjects in Phase 1 Clinical Trial of Drug Candidate NVG-291	23-02-14	MT
NervGen Pharma Announces Completion of Dosing of All Subjects in Phase 1 Clinical Trial of Proprietary Drug Candidate NVG-291	23-02-14	CI
NervGen Pharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Nervgen Pharma Corp. Receives FDA Authorization to Expand Enrollment of Males and Premenopausal Females in Phase 1 Clinical Trial of NervGen's NVG-291	22-10-25	CI
NervGen Pharma Corp. Receives Up to $1.5 Million US Department of Defense Funding to Evaluate NervGen's NVG-291-R for Peripheral Nerve Injury	22-10-12	CI
NervGen Pharma Corp. Announces Executive Changes	22-09-22	CI
NervGen Pharma Corp. Announces Executive Changes	22-09-22	CI
NervGen Pharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-10	CI
NervGen Pharma Corp.(TSXV:NGEN) added to S&P/TSX Venture Composite Index	22-07-18	CI

Chart NervGen Pharma Corp.

Duration

Period

More charts

Company Profile

NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimerâs disease (AD) and multiple sclerosis (MS). Its NVG-291 is a therapeutic peptide, which is a mimetic of the intracellular domain of protein tyrosine phosphatase, a cell surface receptor known to interact with chondroitin sulfate proteoglycans (CSPGs) and to be involved in the regulation of neuroplasticity and central nervous system repair. The Company has two wholly owned subsidiaries, including NervGen US Inc. and NervGen Australia Pty Ltd.

Sector

Biotechnology & Medical Research

Calendar

2024-05-14 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.11 CAD

Average target price

4.5 CAD

Spread / Average Target

+113.27%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NERVGEN PHARMA CORP.	-21.85%	108M
MODERNA, INC.	+29.03%	49.18B
IQVIA HOLDINGS INC.	-0.10%	42.11B
LONZA GROUP AG	+43.45%	40.37B
CELLTRION, INC.	-5.26%	28.85B
ICON PUBLIC LIMITED COMPANY	+11.48%	26.09B
ALNYLAM PHARMACEUTICALS, INC.	-22.74%	18.71B
BIO-TECHNE CORPORATION	+9.06%	13.26B
MEDPACE HOLDINGS, INC.	+30.01%	12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.51%	11.99B

Other Biotechnology & Medical Research